PALIVIZUMAB

PALIVIZUMAB
(pal-i-viz'u-mab)
Synagis
Classifications: immunomodulator; monoclonal antibody; immunoglobulin;
Therapeutic: monoclonal antibody
; immunoglobulin (igg)
Pregnancy Category: C

Availability

100 mg vial

Action

Monoclonal antibody (IgG1k produced by recombinant DNA technology) to the respiratory syncytial virus (RSV).

Therapeutic Effect

Provides passive immunity against respiratory syncytial virus. Indicated by prevention of lower respiratory tract infection.

Uses

Prevention of serious lower respiratory tract infections in children susceptible to RSV.

Contraindications

Hypersensitivity to palivizumab; pregnancy (category C), lactation.

Cautious Use

Hypersensitivity to other immunoglobulin preparations, blood products, or other medications; kidney or liver dysfunction; acute RSV infection.

Route & Dosage

RSV
Child: IM 15 mg/kg qmo during RSV season

Administration

Intramuscular
  • Reconstitute solution by gently injecting 1 mL of sterile water for injection (without preservative) toward the sides of the vial. Gently swirl for 30 sec to dissolve (do not shake solution). Allow to stand at room temperature for at least 20 min until solution clears.
  • Give IM only into the anterolateral aspect of the thigh. Volumes >1 mL should be divided and given in different sites.
  • Use reconstituted solution within 6 h. Discard any unused portion of the vial. It contains no preservatives.

Adverse Effects (≥1%)

Body as a Whole: Otitis media, pain, hernia. GI: Increased AST, diarrhea, nausea, vomiting, gastroenteritis. Respiratory: URI, rhinitis, pharyngitis, cough, wheeze, bronchiolitis, asthma, croup, dyspnea, sinusitis, apnea. Skin: Rash.

Pharmacokinetics

Half-Life: 20 d.

Nursing Implications

Assessment & Drug Effects

  • Lab tests: Periodic monitoring of liver functions may be warranted.
  • Monitor carefully for and immediately report S&S of respiratory illness including fever, cough, wheezing, and retractions.
  • Assess for and report erythema or indurations at injection site.

Patient & Family Education

  • Contact physician if S&S of respiratory illness, vomiting, diarrhea, or redness develop at injection site.

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug

(48)
© 2006-2020 medpill.info Last Updated On: 09/21/2020 (0)
×
Wait 20 seconds...!!!